Friday, 16 October 2026European Markets

IEP INVEST Stock Was Up By 9.8% Today

Loading stream...

(VIANEWS) - The Market ended the session with IEP INVEST (IEP.BR) jumping 9.8% to €5.60 on Monday while BEL 20 rose 0.44% to €3,305.14.

IEP INVEST's last close was €5.10, 13.56% below its 52-week high of €5.90.

About IEP INVEST

Iep Invest, NV is an investment firm specializing in investments in and loans to real estate companies. The firm previously operated as manufacturing group. It was formerly known as Punch International nv and changed its name to Iep Invest, NV in May 2014. Iep Invest, NV was founded in 1982 and is based in Antwerp, Belgium.

Earnings Per Share

As for profitability, IEP INVEST has a trailing twelve months EPS of €-0.22.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -2.4%.

Dividend Yield

As claimed by Morningstar, Inc., the next dividend payment is on Oct 3, 2022, the estimated forward annual dividend rate is 5 and the estimated forward annual dividend yield is 87.72%.

More news about IEP INVEST (IEP.BR).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com